From manufacturers to high volatility biotechs, these are the mind-bending med stocks our Senior Market Strategist is watching now.
Portfolio manager of the AdvisorShares Psychedelics ETF (PSIL) calls executive action a pivotal moment for psychedelic medicine
The first quarter has been marked by scary swings for the U.S. stock market. The S&P 500 achieved an all-time high on Feb. 19 and then slipped into correction territory on March 18 for the first time since...
We are midway through the first quarter. Wall Street has been on a bull run, outplaying tariff trade war fears and concerns over a prolonged pause on Fed rate cuts. The S&P 500 has been hitting new record...
January was full of events and surprises for Wall Street. The major three indices logged gains in the month, with the Dow up 4.7%, the S&P 500 up 2.7% and the Nasdaq up 1.6%. The gains came amid the DeepSeek...
Wall Street has been upbeat in January. The S&P 500 has advanced 3.5% so far this month, the Dow Jones has gained 5.9% and the Nasdaq Composite has added 2.1%. The tech-heavy Nasdaq has been hit hard by...
Chairman Jonathan Javitt said the resources committed are expected to bring NRx to the $100 million revenue threshold.
The brokerage also pointed to potential large-scale expansion opportunities and emphasized the growing acceptance of psychedelics in future treatment paradigms.
Wall Street ended the fourth quarter on a solid note despite the turbulence in the final month. The Nasdaq Composite and the S&P 500 rose for the fifth consecutive quarter for the first time since 2021,...
Cybin’s CEO, Doug Drysdale, noted that the results validate the company’s approach and could revolutionize the standard of care in MDD treatment.